The Drosophila TEAD ortholog Scalloped is required for Yki-mediated overgrowth but is largely dispensable for normal tissue growth, suggesting that its mammalian counterpart may be exploited for selective inhibition of oncogenic growth driven by YAP hyperactivation. Here we test this hypothesis genetically and pharmacologically. We show that a dominant-negative TEAD molecule does not perturb normal liver growth but potently suppresses hepatomegaly/tumorigenesis resulting from YAP overexpression or Neurofibromin 2 (NF2)/Merlin inactivation. We further identify verteporfin as a small molecule that inhibits TEAD-YAP association and YAP-induced liver overgrowth. These findings provide proof of principle that inhibiting TEAD-YAP interactions is a pharmacologically viable strategy against the YAP oncoprotein.
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We showed previously that induction of YAP overexpression starting at 3 wk of age leads to a robust and uniform expansion of liver size, whereas induction of YAP overexpression starting at birth leads to widespread development of hepatocellular carcinoma (HCC) (Dong et al. 2007 ). We used these experimental regimes to test the efficacy of TEAD2-DN in blocking YAP-induced overgrowth and tumorigenesis. In mice subjected to Dox treatment starting at 3 wk of age, expression of TEAD2-DN potently suppressed YAP-induced liver overgrowth (Fig. 1A ,B,E), whereas in mice subjected to Dox treatment starting at birth, expression of TEAD2-DN completely abolished YAP-induced HCC formation ( Fig. 1C-E) . Expression of TEAD2-DN also greatly improved animal survival; in contrast to YAP transgenic mice, which had a mean survival of 7 wk after Dox treatment starting at 3 wk of age, YAP/TEAD2-DN mice showed 100% survival during a 15-wk treatment (Fig. 1F) . Unlike YAP-overexpressing livers, in which hepatocytes are smaller and more densely packed than wild type, YAP/TEAD2-DN livers contained hepatocytes of normal size (Fig. 1B) , suggesting that TEAD2-DN may suppress YAP's ability to promote cell proliferation and/or survival. Indeed, YAP/TEAD2-DN livers showed greatly reduced BrdU incorporation compared with YAP livers (Supplemental Fig. S3A,D) .
Furthermore, unlike YAP-overexpressing livers, which were resistant to Jo-2 (a Fas agonist)-induced hepatocellular apoptosis (Dong et al. 2007 ), Jo-2 treatment induced similar levels of apoptosis in YAP/TEAD2-DN and wild-type livers, as revealed by the widespread hemorrhage and apoptotic nuclei in liver histology and caspase 3 cleavage (Supplemental Fig. S3B,C) . Thus, TEAD2-DN suppressed YAP's proproliferative and anti-apoptotic activities. At mRNA levels, TEAD2-DN reversed the up-regulation of genes that have previously been reported to be transcriptionally induced in YAP transgenic livers, including Afp, Birc5/survivin, c-Myc, Sox4, Ctgf, Opn, Epcam, and Gpc3 (Supplemental Fig. S3E ; Dong et al. 2007 ). Thus, TEAD2-DN can restore YAP-induced gene transcription to wild-type levels. A trivial explanation for the observed suppression of YAP-induced phenotypes by TEAD2-DN is that TEAD2-DN may somehow reduce the expression of the YAP transgene in the double-transgenic livers. We attempted to exclude this possibility by comparing YAP protein levels in YAP versus YAP/TEAD2-DN livers. On the contrary, however, we found that YAP/TEAD2-DN livers always showed significantly increased levels of YAP proteins compared with YAP transgenic livers, irrespective of the length of Dox treatment (Supplemental Fig. S4A ). Quantitative real-time PCR analysis revealed similar levels of human YAP mRNA (from the YAP transgene) and endogenous mouse Yap mRNA in both genotypes (Supplemental Fig. S4B ), suggesting that TEAD2-DN may increase YAP protein levels through a post-transcriptional mechanism; for example, by binding and stabilizing YAP. We tested this hypothesis in HEK293 cells. Indeed, when a GFP-tagged YAP was coexpressed with an increasing amount of HA-tagged TEAD2 or TEAD2-DN, both the exogenous GFP-YAP and the endogenous YAP protein levels were increased (Supplemental Fig. S4C ). We also compared the half-life of wild-type YAP and YAP S94A , a mutant form of YAP that is defective in TEAD binding (Zhao et al. 2008) . YAP S94A had a shorter half-life than wild-type YAP (Supplemental Fig. S4D ), further supporting a role for TEAD in binding and stabilizing YAP.
Next, we tested TEAD2-DN in NF2/Merlin-deficient livers, wherein liver overgrowth and tumorigenesis is driven by activation of endogenous YAP, rather than overexpression of exogenous YAP . For this purpose, we generated Alb-Cre; Nf2 flox2/flox2 ; Alb-rtTA; TEAD2-DN mice (abbreviated as Nf2 TEAD2-DN for simplicity) in which TEAD2-DN can be expressed in a Dox-dependent manner in Nf2 mutant livers. Two Dox treatment regimes were used: a 7-wk treatment starting at gestation, and a 1-yr treatment starting at birth. Expression of TEAD2-DN significantly suppressed the overgrowth of Nf2 mutant livers in both conditions ( Fig. 2A,B) . In the 7-wk treatment group, TEAD2-DN abolished the development of bile duct hamartoma that were otherwise detectable (with 100% penetrance) on the surface of Nf2 mutant liver lobes ( Fig. 2A) . In the 1-yr treatment group, Nf2-deficient livers typically showed expansive bile duct hamartoma comprised of masses of cytokeratin (CK)-positive biliary epithelial cells (BECs) that have invaded deep into the liver parenchyma, as well as HCC (with 100% penetrance) and greatly increased liver weight ( Fig. 2B-E) . In 1-yr-old Nf2 TEAD2-DN livers, hamartoma development was greatly suppressed and no HCC was observed ( Fig. 2B-D) , resulting in a liver size comparable with that of wild-type mice (Fig. 2E) . Consistent with phenotypic suppression, TEAD2-DN potently suppressed the up-regulation of YAP target genes in Nf2-deficient livers (Supplemental Fig.  S5 ) in much the same way that TEAD2-DN reversed the up-regulation of these genes in YAP-overexpressing livers (Supplemental Fig. S3E ). Importantly, overexpression of TEAD2-DN by itself (using Alb-rtTA; TRE-TEAD2-DN mice) did not affect liver size, liver histology, or expression of YAP target genes (Supplemental Fig. S6 ). Thus, much like in Drosophila, where Sd is required for overgrowth driven by hyperactive Yki but is dispensable for normal growth in most imaginal tissues, TEAD2-DN can prevent hepatomegaly and liver tumorigenesis caused by YAP hyperactivation without compromising normal liver homeostasis. In this page In a new window Download as PowerPoint Slide hyperplasia and the absence of HCC in the Nf2 TEAD2-DN liver. (E) Quantification of liver-to-body weight ratio for animals analyzed in A and B. (7WG) Dox treatment for 7 wk starting at gestation; (1YB) Dox treatment for 1 yr starting at birth. n ≥ 6 for each data point. In both conditions, the overgrowth of Nf2 mutant livers was significantly suppressed in Nf2 TEAD2-DN livers (P = 1 × 10 −5 and 1 × 10 −7 , respectively).
The striking ability of TEAD2-DN to suppress hepatomegaly and liver tumorigenesis caused by YAP overexpression or loss of NF2, combined with the inconsequentiality of TEAD2-DN on normal liver homeostasis, suggests that the TEAD-YAP transcription factor complex may offer an ideal drug target for selective inhibition of YAP-induced tumorigenesis. Thus, small molecules that inhibit the physical association between YAP and TEAD may provide a pharmacological approach for inhibiting TEAD function. To screen for such inhibitors, we took advantage of an established luciferase reporter assay in which transcriptional activity of a Gal4-TEAD4 fusion is stimulated by YAP (Zhao et al. 2008) . Using this reporter assay, we screened the Johns Hopkins Drug Library, a collection of >3300 drugs that have been approved by the United States Food and Drug Administration or its foreign counterparts or have entered phase II clinical trials (Chong et al. 2007 ). We identified 71 hits that inhibited luciferase activity by >30% at a concentration of 10 μM (Fig. 3A) . Three compounds (protoporphyrin IX [PPIX] , hematoporphyrin [HP] , and verteporfin [VP]) stood out among the top hits, as they all belong to the porphyrin family, which are aromatic heterocyclic cyclic molecules composed of four modified pyrrole units interconnected at their α carbon atoms via methine bridges.
Coincidently, the same three porphyrin molecules were also identified as top hits in an independent FRET-based Yki-Sd interaction screen (data not shown).
To confirm that these hits indeed disrupted physical interactions between YAP and TEAD, we performed coimmunoprecipitation (co-IP) assays in HEK293 cells expressing GAL4-TEAD4 and HA-YAP that had been treated with the test compounds at various concentrations or the solvent control DMSO (Fig. 3B ).
While treatment with HP did not cause appreciable inhibition at 10 μM (data not shown), treating cells with the other two porphyrins (VP and PPIX) at 10 μM dramatically reduced the amount of GAL4-TEAD recovered in the immunoprecipitates of HA-YAP, indicating that these two drugs significantly disrupted YAP-TEAD interactions (Fig. 3B) . Interestingly, VP displayed stronger inhibitory effects than PPIX, as >50% inhibition could still be observed when VP was titrated down to 2.5 μM, while 5 μM PPIX had negligible effects. Thus, we identified VP and PPIX as the first small molecule inhibitors targeting the physical interactions between YAP and TEAD. VP (trade name Visudyne by Novartis) is used clinically as a photosensitizer in photodynamic therapy for neovascular macular degeneration, where it is activated by a special wavelength laser light to generate reactive oxygen radicals that eliminate the abnormal blood vessels (Michels and Schmidt-Erfurth 2001) . The inhibitory activity of VP on YAP-TEAD interactions apparently did not require light activation, since all of our binding assays were conducted in darkness. To investigate how VP inhibits YAP-TEAD interactions, we determined whether VP directly binds to purified YAP or TEAD protein, taking advantage of porphyrin's intrinsic fluorescence emission (Rotomskis et al. 1989 ). Bacterially purified YAP or TEAD2 was incubated with VP, and the mixture was then analyzed on a size exclusion column to examine whether VP coelutes with either protein. An appreciable VP fluorescence coeluted with the YAP protein peak but not with the TEAD2 protein peak, demonstrating that VP selectively binds YAP (Fig. 3C) .
We further investigated the binding of VP to YAP or TEAD2 by analyzing proteolytic profiles of the respective protein in the presence of VP, a method that is widely used to determine binding of a small molecule to its target protein and to probe conformational changes of proteins (Yun et al. 2004) . Direct binding of a small molecule to a protein can cause conformational changes that are accompanied by alteration in proteolysis patterns of the protein by proteases such as trypsin. Under the optimal cleavage conditions for each protein, 20 μM VP significantly enhanced the trypsin cleavage of YAP over time, while it had no effect on the cleavage of TEAD2 (Fig. 3D) . In addition, VP dose-dependently accelerated trypsin cleavage of YAP with an EC 50 (half maximal effective concentration) value of 0.1 μM (Fig. 3E) . These results suggest that VP binds to YAP and enhances the accessibility of trypsin to YAP, presumably by In this page In a new window Download as PowerPoint Slide changing the conformation of YAP. Taken together, we conclude that VP binds to YAP and changes its conformation, thereby abrogating its interaction with TEAD2.
Given the considerable functional conservation between the mammalian TEAD-YAP complex and its Drosophila counterpart, we tested whether the porphyrins could inhibit the Yki-Sd complex in Drosophila cells. S2R + cells expressing Myc-Yki and HA-Sd were treated with VP or PPIX, and the amount of HA-Sd recovered in the Myc-Yki immunoprecipitates was measured as an indication of Sd-Yki association. Consistent with their relative potencies against the TEAD-YAP complex in mammalian cells, VP exhibited robust dose-dependent inhibition of Sd-Yki interaction that became apparent at 200 nM, whereas PPIX showed a milder inhibitory effect than VP, with an estimated IC 50 (half maximal inhibitory concentration) between 5 and 10 μM (Supplemental Fig.   S7A ). VP also inhibited the interaction between endogenous Yki and transiently expressed HA-Sd in S2 cells (Supplemental Fig. S7B ). Interestingly, we noted that VP treatment of S2 cells led to a reduction in protein and mRNA levels of endogenous diap1, a direct transcription target of Yki (Supplemental Fig. S7B ). These results demonstrate that VP induces transcriptional changes in Drosophila cells that are consistent with inhibition of the Sd-Yki complex.
Next, we examined the ability of VP to inhibit the oncogenic activity of YAP in vivo using two independent assays. In the first assay, we tested VP's ability to suppress YAP-induced hepatomegaly using the inducible YAP transgenic mouse model described above. The ApoE-rtTA/TRE-YAP mice were injected with VP (100 mg/kg) every other day over a period of 8 d, while these mice were kept on Dox throughout the course of experiment (Fig. 4A) . Compared with the control group (Dox+DMSO), the VP-treated group (Dox+VP) exhibited a smaller increase in liver size and a decreased number of mitotic cells (Fig. 4B,C) .
Importantly, VP treatment did not interfere with YAP transgene expression (Supplemental Fig. S8A ) or affect liver size in wild-type control (i.e., nontransgenic) mice (Supplemental Fig. S8B ). In the second assay, we tested VP in mice bearing liver-specific knockout of NF2/Merlin, which exhibited bile duct overproliferation due to activation of endogenous YAP . Pregnant mothers bearing Alb-Cre; Nf2 flox2/flox2 embryos received VP injections (100 mg/kg) every other day starting at embryonic day 9 (E9) of the Alb-Cre; Nf2 flox2/flox2 embryos until birth (Fig. 4D) , and BECs were visualized by CK staining at E18.5. As shown in Figure 4E , the number of CK-positive BECs was significantly reduced in VP-treated Nf2-deficent livers compared with control-treated Nf2-deficient livers. Thus, VP suppressed liver overgrowth resulting from either YAP overexpression or activation of endogenous YAP. These results are encouraging, since VP is a clinically applied drug with little side effects, and our results were obtained using an aqueous preparation in which VP bioavailability is suboptimal compared with the lipid-based formulation used in Visudyne. A major challenge in cancer research is the identification of cellular targets whose inhibitions selectively impair the growth of cancer cells while sparing normal cells (Luo et al. 2009 ). We demonstrate here that one can exploit the intrinsic property of a growth regulatory pathway; namely, the preferential requirement of TEAD/TEF transcription factors for oncogenic over normal growth as a selective means to inhibit YAP-induced tumorigenesis. The inconsequentiality of TEAD2-DN on normal liver homeostasis suggests that this strategy may offer an excellent "therapeutic window" with minimal adverse effects. As a proof of principle for this approach, we conducted a pilot screen and identified VP as a small molecule that inhibits TEAD-YAP interactions and prevents YAP-induced oncogenic growth. Whether VP or its derivatives are effective on pre-established tumors awaits future investigation. Finally, the efficacy of TEAD2-DN and VP in suppressing Nf2-deficient phenotypes lends further support for a functional link between NF2/Merlin and Hippo signaling (Hamaratoglu et al. 2006; Zhang et al. 2010) and offers the promise of YAP inhibitors as molecular targeted therapeutics for NF2, a genetic disorder caused by inactivation of the NF2/Merlin tumor suppressor.
Materials and methods

Chemical screen
Twenty-five-thousand HEK293 cells per well in 96-well plates were transfected (Effectene, Qiagen) with 8 ng of pHA-YAP, pGal4-TEAD4, and 5× UAS-Luc and 0.4 ng of Pol III renilla luciferase. Library compounds were dispensed into each well immediately after transfection at a final concentration of 10 μM. After 16 h, cell lysates were examined for firefly luciferase activity relative to renilla luciferase with the Dual-Luciferase Reporter Assay kit (Promega) and a FLUOstar OPTIMA microplate reader (BMG).
